Feds reject Lilly’s fast-track application for Alzheimer’s drug
Federal regulators have rejected Eli Lilly and Co.’s application for accelerated approval of an experimental treatment for Alzheimer’s disease due to a limited number of patients that were still on the drug for a full year in clinical trials.... Read More